Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 76

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 76
---
 2024, (ii) Vice Chairman of the board of directors of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. |

On April 22, 2025, pursuant
to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth
PIPE Financing”), 6,250 shares of the Series D Preferred Stock to investors in exchange for the receipt of 1,000,279 shares of the
Stella Series D Preferred Stock in lieu of cash, in which a portion of the Stella Series D Preferred Stock was owned by a related party
investor. The investor is a majority shareholder of Stella Diagnostics, Inc. and has representation on the board of directors thereof.
The related shares of the Stella Series D Preferred Stock were resold to the related party investor in the three months ended September
30, 2025 (see Note 10).

During the nine months ended
September 30, 2025 and for the period from February 14, 2024 to September 30, 2024, the Company incurred consulting fees of $190,000 and
$75,000 to members of the Company’s board of directors, respectively.

NOTE 14 – SUBSEQUENT EVENTS

Series E Preferred Stock

On October 14, 2025, the Company entered into
the Fifth Securities Purchase Agreement with certain accredited investors named therein, pursuant to which the Company agreed to issue
and sell up to 9,750 shares of the Company’s Series E Preferred Stock for an aggregate purchase price of up to $7 million in one
or more closings. On October 15, 2025, the Company and the requisite buyers party to the Fifth Securities Purchase Agreement entered
into Amendment No. 1 to the Securities Purchase Agreement (the “SPA Amendment”) to add an additional Buyer (as defined in
the Fifth Securities Purchase Agreement) and increase the size of the Initial Closing (as defined in the Fifth Securities Purchase Agreement)
by $500,000 to an aggregate of approximately $2.25 million of gross proceeds and reduce the size of the Additional Closings (as defined
in the Fifth Securities Purchase Agreement) by an offsetting amount. There was no change to the aggregate amount of up to $7 million of
proceeds to be funded pursuant to the Fifth Securities Purchase Agreement upon consum